Pneumococcal polysaccharide-RSV recombinant protein conjugate vaccine and preparation method therefor
By performing amino acid mutations on the RSV Pre-F protein and binding to pneumococcal polysaccharides, the prepared vaccine solves the shortcomings of the existing vaccines, achieves dual prevention of pneumococcal and RSV, and improves the protective effect and safety of the vaccine.
Patent Information
- Application Number
- PCT/CN2024/131554
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-01-26
- Filing Date
- 2024-11-12
- Publication Date
- 2025-07-31
AI Technical Summary
The existing pneumococcal and RSV vaccines have problems such as the carrier protein without immunogenic protection function, unable to cover all serotypes, requiring multiple enhancement of immunity and limited protection effect. There are problems such as the risk of strengthening disease and poor protein stability in the development of RSV vaccines.
By modifying the RSV Pre-F protein with amino acid mutations to enhance its stability, and binding it as a carrier protein to pneumococcal polysaccharides, pneumococcal polysaccharide-RSV recombinant protein binding vaccine, protein expression and purification were performed using CHO cells and insect baculovirus expression systems, and binding was prepared using chemical synthesis methods.
It achieves dual immunogenicity, can prevent pneumococcal and RSV infections at the same time, improves the protective effect and safety of the vaccine, reduces the number of vaccinations, enhances antigenicity and stability, and provides a wider protection effect.